Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Revenue (2020 - 2025)

Maxcyte (MXCT) has disclosed Revenue for 6 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 154.86% to -$4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.0 million through Dec 2025, down 36.24% year-over-year, with the annual reading at $21.0 million for FY2025, 45.75% down from the prior year.
  • Revenue for Q4 2025 was -$4.8 million at Maxcyte, down from $6.8 million in the prior quarter.
  • The five-year high for Revenue was $23.3 million in Q4 2022, with the low at -$6.1 million in Q4 2023.
  • Average Revenue over 5 years is $7.1 million, with a median of $8.3 million recorded in 2024.
  • The sharpest move saw Revenue soared 1171.97% in 2022, then crashed 154.86% in 2025.
  • Over 5 years, Revenue stood at -$2.2 million in 2021, then skyrocketed by 1171.97% to $23.3 million in 2022, then crashed by 126.33% to -$6.1 million in 2023, then soared by 241.9% to $8.7 million in 2024, then plummeted by 154.86% to -$4.8 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at -$4.8 million, $6.8 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.